title: [Anaemia and radiation therapy].
abstract: Anaemia is frequent in cancer and may increase tumour hypoxia that stimulates angiogenesis. However, erythropoietin is a hypoxia-inducible stimulator of erythropoiesis which seems to improve quality of life in cancer patients. Two recent phase III randomized studies showed negative results using erythropoietin in head and neck cancer patients and in metastatic breast cancer patients with impaired specific survival. In vitro and in vivo experiments have provided erythropoietin-receptor expression in endothelial cancer cells including malignant tumours of the breast, prostate, cervix, lung, head and neck, ovary, melanoma, stomach, gut, kidney etc. Biologic effect of erythropoietin and its receptor linkage induces proliferation of human breast cancer and angiogenesis and may limit anti-tumour effect of cancer treatment, in part, by tumour vascularization improvement. In addition, the use of exogenous erythropoietin could be able to favour tumour progression by improving tumour oxygenation and nutriment supply. If erythropoietin receptor were functional in human cancer, the assessment of erythropoietin receptor expression on tumour cell may help to select patients benefiting from exogenous erythropoietin. However, the relationship between erythropoietin receptor expression, tumour growth and exogenous erythropoietin, requires more studies. The results of recent clinical trials suggest that using erythropoietin should be avoided in non-anemic patients and discussed in patients receiving curative therapy.
authors.affiliation: Clinique d'oncologie et de radiothérapie, INSERM U619, CHU, 37044 Tours, France. fcdenis@club-internet.fr
authors.forename: F
authors.initials: F
authors.lastname: Denis
authors.forename: E
authors.initials: E
authors.lastname: Lartigau
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000737:chemistry / Q000401:mortality / Q000532:radiotherapy*; D009374:Neoplasms, Experimental / Q000532:radiotherapy; D009389:Neovascularization, Pathologic; D011379:Prognosis; D051381:Rats; D017467:Receptors, Erythropoietin / Q000032:analysis
chemical_list: D017467:Receptors, Erythropoietin; D004921:Erythropoietin